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1 INTRODUCTION 
Exchange rate is one of the biggest economic issues 
because fluctuation of exchange rate could harm any 
businesses, which use different currencies in their 
daily operation. In 2018, Federal Reserve continued 
to raise its US benchmark interest rate, in line with 
increasing inflation. Rupiah faced considerable pres-
sure with the rising of US interest rate, touching 
above Rp 14,500 per US Dollar. Correspondingly, 
Bank Indonesia’s benchmark interest rate was hiked 
several times, up by 175 basis points to 6.0% in 
2018. As a result, Indonesia closed the year with a 
moderate 5.17% growth, slightly higher than the 
GDP growth in 2017 (5.07%). 
The weakening condition of Rupiah above 14,500 
per US Dollar is being judged as the failure of eco-
nomic policy by domestic manufacturers, which rely 
hardly on the use of imported raw materials. The 
continual increase in production cost in a short time 
could indirectly decrease the product demand and 
hence affecting the net profit. 
One of the industries, which really affected by the 
weakening condition of Rupiah, is pharmacy indus-
try because 90-95% of the raw materials are import-
ed from some countries, such as China, India, Japan, 
and some European countries, using US Dollar as 
the currency. 
PT Kalbe Farma, Tbk is one of the pharmacy 
manufacturers, which affected by the weakening 
condition of Rupiah. This paper aims to analyze the 
strategies used by PT Kalbe Farma, Tbk in order to 
overcome the situation. 
1.1 PT Kalbe Farma, Tbk. 
PT Kalbe Farma, Tbk started back in 1966, guided 
by “Panca Sradha”, the company’s living values, PT 
Kalbe Farma, Tbk has since grown and developed to 
become one of Indonesia’s most respected business 
institution and went public in 1991, listed in Indone-
sia Stock Exchange. Through organic growth and 
mergers & acquisitions, PT Kalbe Farma, Tbk ex-
pands its business interests and transforms to be-
come provider of an integrated healthcare solution 
through its four business divisions: the prescription 
pharmaceuticals, consumer health, nutritionals, and 
distribution & logistics divisions. All of these busi-
ness divisions manage a comprehensive portfolio of 
prescription pharmaceuticals and OTC drugs, nutri-
tionals, and medical devices, serving over one mil-
lion outlets across Indonesia. In the international 
Kalbe Farma and weakening Rupiah 
S.L. Swandono, K. Raesita & P.A. Mahadwartha 
Universitas Surabaya, Surabaya, Indonesia 
 
 
 
 
 
 
 
 
 
ABSTRACT: This case study aims to analyze the strategies used by PT Kalbe Farma, Tbk, a pharmacy com-
pany listed in Indonesia Stock Exchange, regarding to weakening condition of Rupiah. Pharmacy companies 
rely hardly on the usage of imported raw materials and the weakening condition of Rupiah would negatively 
affect their net profit. The strategies used by PT Kalbe Farma, Tbk successfully increasing the net profit in the 
year 2018 by 4.5%.  
